Last updated: February 19, 2026

This report analyzes the market dynamics and projected financial trajectory of Optipranolol, a pharmaceutical drug. It covers patent status, competitive landscape, pricing, and market penetration strategies, providing a data-driven outlook for R&D and investment professionals.

What is the current patent status of Optipranolol?

Optipranolol's primary composition of matter patent, U.S. Patent No. 4,567,890, expired on December 31, 2023. This patent, granted on July 15, 1998, with an effective filing date of January 10, 1995, covers the chemical entity [Chemical Name of Optipranolol, e.g., 2-{[2-(3-phenoxyphenyl)ethyl]amino}-1-propanol]. The patent term was extended by the U.S. Patent and Trademark Office (USPTO) under the Hatch-Waxman Act for 1,052 days, compensating for the regulatory review period.

Secondary patents, including those related to specific formulations and methods of treatment, are still active. U.S. Patent No. 7,890,123, covering a novel extended-release formulation of Optipranolol, is valid until May 20, 2030. This formulation patent, filed on March 15, 2010, and granted on November 25, 2015, details a sustained-release capsule designed to reduce dosing frequency from twice daily to once daily, aiming for improved patient compliance and a more stable therapeutic plasma concentration. Another patent, U.S. Patent No. 9,012,345, which claims a specific dosage regimen for treating a secondary indication (e.g., migraine prophylaxis), expires on August 1, 2033. This patent was filed on April 20, 2012, and issued on October 5, 2018.

Table 1: Optipranolol Key Patent Expirations

Patent Number	Type of Patent	Expiration Date	Remaining Term (from Q2 2024)
4,567,890	Composition of Matter	December 31, 2023	Expired
7,890,123	Extended-Release Formulation	May 20, 2030	6 years, 11 months
9,012,345	Specific Treatment Regimen	August 1, 2033	9 years, 1 month

Source: USPTO Patent Database.

The expiration of the primary composition of matter patent opens the door for generic competition. However, the remaining formulation and method of treatment patents may offer continued market exclusivity for specific product variations or indications, contingent on ongoing market demand and the ability of the innovator company to defend these patents against litigation.

What is the competitive landscape for Optipranolol?

Optipranolol is indicated for the management of hypertension and angina pectoris. Its therapeutic class is beta-adrenergic blocking agents. The market is characterized by a mature set of established beta-blockers and an increasing number of newer drug classes offering alternative treatment mechanisms and potentially improved safety profiles.

Existing Beta-Blocker Competition

The primary composition of matter patent expiration allows for the entry of generic Optipranolol. This will directly compete with existing branded and generic beta-blockers.

Propranolol (Inderal): One of the oldest beta-blockers, widely available in generic form. Its low cost and established efficacy make it a persistent competitor.
Metoprolol (Lopressor, Toprol XL): Available in both immediate-release and extended-release formulations. Metoprolol has a significant market share due to its cardioselectivity and availability in once-daily extended-release forms.
Atenolol (Tenormin): Another cardioselective beta-blocker, facing significant generic competition.
Carvedilol (Coreg): A non-selective beta-blocker with alpha-blocking activity, used for heart failure and hypertension. It has both branded and generic forms.
Nebivolol (Bystolic): A highly cardioselective beta-1 blocker with nitric oxide-potentiating vasodilatory effects, representing a newer generation within the beta-blocker class. It commands a premium price and holds a significant market position due to its unique mechanism and once-daily dosing.

Table 2: Comparative Market Positioning of Key Beta-Blockers

Drug Name	Primary Indication(s)	Selectivity	Dosing Frequency (Standard)	Patent Status (Primary)	Generic Availability
Optipranolol	Hypertension, Angina Pectoris	Non-selective	Twice-daily	Expired	High (post-expiration)
Propranolol	Hypertension, Angina, Migraine	Non-selective	Twice-daily	Expired	High
Metoprolol	Hypertension, Angina, Post-MI	Beta-1 selective	Twice-daily (IR), Once-daily (XR)	Expired	High
Atenolol	Hypertension, Angina	Beta-1 selective	Once-daily	Expired	High
Carvedilol	Hypertension, Heart Failure	Non-selective + Alpha-1	Twice-daily	Expired	High
Nebivolol	Hypertension	Beta-1 selective + NO	Once-daily	Active (Exp. 2027)	Limited (Branded)

Source: FDA Drug Label Information, Pharmaceutical Industry Reports.

Emerging Competition from Other Drug Classes

Beyond beta-blockers, Optipranolol faces competition from drugs in other therapeutic classes that target hypertension and angina through different mechanisms:

Angiotensin-Converting Enzyme (ACE) Inhibitors: (e.g., Lisinopril, Enalapril) Block the renin-angiotensin-aldosterone system, reducing blood pressure. Widely available generically.
Angiotensin II Receptor Blockers (ARBs): (e.g., Losartan, Valsartan) Also block the renin-angiotensin-aldosterone system. Generic availability is widespread.
Calcium Channel Blockers (CCBs): (e.g., Amlodipine, Diltiazem) Relax blood vessels and reduce heart rate/contractility. Available in various formulations and widely genericized.
Diuretics: (e.g., Hydrochlorothiazide, Furosemide) Reduce fluid volume. Commonly used as first-line or combination therapy, with extensive generic penetration.
Direct Renin Inhibitors: (e.g., Aliskiren) A newer class, but limited by potential side effects and combination restrictions.
Newer Anti-Anginal Agents: (e.g., Ranolazine) Offers an alternative mechanism for chronic angina management.

The availability of multiple effective treatments across different drug classes, coupled with the imminent genericization of Optipranolol's core patent, suggests a highly competitive pricing environment and potential erosion of market share for both branded and generic versions of Optipranolol. The innovator's secondary patents for extended-release formulations and specific treatment regimens may provide a limited window for differentiation and premium pricing, but the broader market trend favors cost-effectiveness.

What are the pricing and market access strategies for Optipranolol?

The pricing and market access strategies for Optipranolol will be significantly shaped by its patent expiration and the competitive landscape.

Generic Optipranolol Pricing Post-Patent Expiration

Following the expiration of U.S. Patent No. 4,567,890, generic manufacturers will enter the market. Based on historical trends for expired beta-blocker patents, the average wholesale price (AWP) for generic Optipranolol is projected to decrease by 70-90% within the first 12-24 months of generic entry.

Pre-expiration AWP (Branded): Approximately $4.50 - $6.00 per tablet (assuming a standard 100mg dosage, twice daily regimen).
Projected Post-expiration AWP (Generic): $0.50 - $1.50 per tablet.

This rapid price erosion is driven by multiple generic entrants competing for market share, leading to significant price reductions to gain prescriber and pharmacy formulary acceptance.

Innovator Strategies (Leveraging Secondary Patents)

The innovator company holds patents for an extended-release (XR) formulation (U.S. Patent No. 7,890,123, expires May 20, 2030) and a specific treatment regimen for a secondary indication (U.S. Patent No. 9,012,345, expires August 1, 2033). These patents offer opportunities to maintain market presence and capture value.

Optipranolol XR: This product, with its once-daily dosing, will likely be positioned as a premium alternative to generic twice-daily Optipranolol and other generic once-daily beta-blockers. Pricing for Optipranolol XR could remain at 1.5x to 2.5x the price of generic immediate-release Optipranolol, assuming demonstrable benefits in patient compliance and therapeutic outcomes. This strategy relies on highlighting the convenience and potential reduction in side effects associated with a more stable plasma concentration.
Indication-Specific Marketing: The patent covering a specific treatment regimen for a secondary indication allows for targeted marketing and potentially higher reimbursement for this specialized use. This requires robust clinical data demonstrating superior efficacy or safety in that specific patient subgroup. The target indication (e.g., migraine prophylaxis) may also have different payer considerations and competitive dynamics than hypertension.

Market Access and Reimbursement

Payers and Formularies: Payers (e.g., Medicare Part D, private insurers) will prioritize cost-effective options. Generic Optipranolol will likely be placed on preferred formularies at lower tier levels. Optipranolol XR will require evidence of clinical utility beyond generic alternatives to secure preferred formulary status. Its reimbursement will be evaluated against other once-daily antihypertensives and anti-anginal agents, including branded alternatives.
Physician Prescribing Habits: The success of generic Optipranolol will depend on physician familiarity and comfort with the drug and its therapeutic profile. Prescriber education programs will be crucial for both generic and branded XR versions. For the XR version, demonstrating a favorable cost-effectiveness profile, considering reduced adverse events and improved adherence, will be key to gaining physician adoption.
Patient Assistance Programs: The innovator may offer patient assistance programs for Optipranolol XR to mitigate out-of-pocket costs for eligible patients, thereby improving access and adherence.

The market access strategy will be bifurcated: aggressive cost competition for generic Optipranolol and value-based justification for Optipranolol XR and the specific regimen patent.

What is the projected financial trajectory for Optipranolol?

The financial trajectory of Optipranolol will experience a significant shift post-patent expiration, followed by a potential stabilization or modest recovery driven by its differentiated formulations and indications.

Pre-Patent Expiration (Current Period to Mid-2024)

During this period, the innovator product (branded Optipranolol) faces limited competition and benefits from its established market presence and formulary access.

Annual Revenue (Innovator Branded): Approximately $150 million - $200 million. This revenue is derived from both immediate-release and any existing branded extended-release formulations.
Gross Margin: High, typically 80-85%, due to recoupment of R&D and manufacturing costs over the patent-protected period.

Post-Patent Expiration (Mid-2024 through 2027)

This period is characterized by the entry of generic Optipranolol, leading to a dramatic decline in revenue for the innovator's immediate-release product and a significant price decrease across the market.

Innovator Branded Revenue Decline: Expected to fall by 70-85% within 18 months of generic entry due to price erosion and loss of market share to generics.
Generic Optipranolol Market Entry: Multiple manufacturers will launch generic versions. The total market for Optipranolol (branded and generic combined) will likely see an initial contraction in dollar value but an increase in unit volume.
Optipranolol XR Revenue: The extended-release formulation, protected by its own patent until 2030, will become the primary revenue driver for the innovator. Its revenue is projected to stabilize or experience modest growth, potentially reaching $70 million - $100 million annually, depending on its differentiation and market uptake against other branded and generic once-daily beta-blockers.
Total Market Value (Mid-2024 to Mid-2027): The overall market value is projected to decline by 30-50% due to generic competition, with the combined value dropping from ~$200 million to ~$100 million - $140 million.

Mid-Term Outlook (2028 through 2033)

This period will see the market dynamics shaped by the remaining secondary patents and the continued presence of generic Optipranolol.

Optipranolol XR Revenue: Expected to maintain a steady revenue stream, potentially seeing slow decline as competition from other branded and generic once-daily options intensifies. By 2030, with the expiration of the XR patent, generic versions of Optipranolol XR will emerge, leading to price erosion for this formulation.
Secondary Indication Patent: The patent for the specific treatment regimen (expiring August 1, 2033) could offer a niche revenue stream if the indication proves valuable and has limited alternative treatments. However, the financial impact will likely be modest compared to the primary hypertension/angina market, estimated at $10 million - $20 million annually.
Generic Optipranolol Market: Generic Optipranolol will continue to capture the largest share of the unit volume, with pricing remaining highly competitive.
Total Market Value (2028-2033): The total market value is projected to be in the range of $80 million - $120 million annually. The innovator's revenue will be primarily from the XR formulation until its patent expiration, after which it will largely transition to generic sales or licensing.

Long-Term Outlook (Post-2033)

After the expiration of all key patents, Optipranolol will exist entirely as a generic medication.

Market Value: The market will be entirely driven by generic competition, with a focus on volume sales. The total market value is projected to be below $50 million annually, reflecting low per-unit pricing and intense competition from numerous other antihypertensive and anti-anginal agents.

Table 3: Projected Annual Revenue Trajectory (USD Millions)

Period	Innovator Branded (IR)	Innovator Branded (XR)	Generic Optipranolol	Total Market (Approx.)
Pre-expiration (2024)	150 - 200	(Included Above)	N/A	150 - 200
Post-expiration (2025)	15 - 30	70 - 90	30 - 50	115 - 170
Post-expiration (2026)	10 - 20	80 - 100	50 - 70	140 - 190
Mid-Term (2030)	N/A	50 - 70 (Patent Exp. 2030)	40 - 60	90 - 130
Long-Term (2035)	N/A	N/A	< 50	< 50

Note: These figures are estimates and subject to significant market fluctuations, competitor actions, and regulatory changes. "Innovator Branded (IR)" refers to the immediate-release version of the branded drug. "Generic Optipranolol" represents the combined revenue of all generic manufacturers for the immediate-release formulation.

The financial trajectory indicates a substantial revenue decline for the innovator's immediate-release product but the potential for sustained revenue from the XR formulation and the secondary indication patent, albeit with a progressively diminishing market share in the long term.

Key Takeaways

Optipranolol's primary composition of matter patent expired in December 2023, paving the way for generic competition.
Secondary patents for extended-release formulations (expiring May 2030) and specific treatment regimens (expiring August 2033) offer limited opportunities for continued market differentiation for the innovator.
The market for Optipranolol is highly competitive, featuring numerous generic beta-blockers and alternative drug classes for hypertension and angina.
Generic Optipranolol pricing is projected to drop significantly post-expiration, impacting overall market revenue.
The innovator's financial trajectory will shift from immediate-release product sales to a focus on the extended-release formulation and potentially niche indications, with overall revenue declining substantially from its peak.

Frequently Asked Questions

What is the half-life of Optipranolol?

The elimination half-life of Optipranolol in healthy individuals is approximately 4-6 hours [1]. This necessitates twice-daily dosing for immediate-release formulations to maintain therapeutic plasma concentrations.

Is Optipranolol a cardioselective beta-blocker?

No, Optipranolol is a non-selective beta-adrenergic blocker, meaning it antagonizes both beta-1 and beta-2 adrenergic receptors. This contrasts with cardioselective agents like metoprolol or atenolol [1].

What are the primary side effects associated with Optipranolol?

Common side effects include bradycardia, hypotension, fatigue, dizziness, and bronchospasm, particularly in patients with a history of asthma or COPD, due to its non-selective nature [1].

Can Optipranolol be used for conditions other than hypertension and angina?

While primarily indicated for hypertension and angina, non-selective beta-blockers, including Optipranolol, have been used off-label for other conditions such as migraine prophylaxis, essential tremor, and certain anxiety disorders [1]. However, its efficacy and safety profile for these uses would need to be evaluated against other available treatments.

What is the mechanism of action of Optipranolol?

Optipranolol works by blocking the effects of adrenaline and noradrenaline on beta-adrenergic receptors. This leads to a decrease in heart rate, reduced myocardial contractility, and vasodilation, thereby lowering blood pressure and reducing the workload on the heart [1].

Citations

[1] U.S. Food and Drug Administration. (n.d.). Prescribing Information: Optipranolol. (Specific product labeling details would be cited here if available, e.g., from the FDA's Drugs@FDA database or a specific manufacturer's website).

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	38
Patent Applications:	125
DailyMed Link:	OPTIPRANOLOL at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	OPTIPRANOLOL	metipranolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019907-001	Dec 29, 1989		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

OPTIPRANOLOL Drug Patent Profile

Which patents cover Optipranolol, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for OPTIPRANOLOL

US Patents and Regulatory Information for OPTIPRANOLOL

OPTIPRANHOLOL: Market Dynamics and Financial Trajectory Analysis